DMX-700 / Dimerix - LARVOL DELTA

DIMERIX DATA DEMONSTRATING DMX-700 EFFECT ON KEY COPD RECEPTORS (Listcorp) - "Dimerix...today announced additional positive invitro data to support further developmentof its drug candidate DMX-700 to treat chronic obstructive pulmonary disease (COPD), the fourth-leading cause of death in the world...Professor Pfleger will present some of the technical DMX-700 data on the IL-8Rβ and AT1R heteromer interactionon 8 October 2020 as part of the GPCRs in drug discovery session...a virtual conference being held online 6-16 October 2020. The DMX-700 development plan will continue to progress towards the clinical phase...The PCT global patent application, number [PCT/AU2020/050987], has a filing date of 18 September 2020 and a priority date of 26 September 2019 and once granted would expire post 2040."

Patent • Preclinical • Chronic Obstructive Pulmonary Disease • Respiratory Diseases